|By Marketwired .||
|March 3, 2014 01:44 PM EST||
BRISBANE, AUSTRALIA -- (Marketwired) -- 03/03/14 -- Alchemia Limited (ASX: ACL), a drug discovery and development company, today announced that Thomas Liquard, the Company's Chief Executive Officer, will present a corporate overview at the 26th Annual ROTH Conference. Mr Liquard's presentation will take place on Wednesday, March 12th, 2014 at 10:00AM PST at The Ritz Carlton in Dana Point, California.
Slides from the presentation will be posted to the ASX and available on Alchemia's website at http://www.alchemia.com.au at the time of the presentation.
About Alchemia Limited
Alchemia is a drug discovery and development company marketing FDA approved fondaparinux, an injectable antithrombotic in the US, as well as other major markets via partner Dr. Reddy's Laboratories. The Company is also developing a late stage oncology product pipeline with multiple ongoing trials through its proprietary HyACT drug delivery platform, which targets anti-cancer drugs to solid tumours. Lead asset HA-Irinotecan is in a pivotal Phase III clinical trial for the treatment of metastatic colorectal cancer. HA-Irinotecan is also in two Phase II investigator-sponsored trials, one of which is in collaboration with Merck Serono combining HA-Irinotecan with Erbitux® (cetuximab). Alchemia is also exploring additional small molecule drug discovery targets via an internal discovery platform VAST, based on the Company's deep chemistry expertise. The VAST technology is being developed in collaboration with leading academic institutions and is partnered with AstraZeneca AB.
Arixtra® is a trademark of GlaxoSmithKline plc, Erbitux® is a trademark of Merck KGaA.
Chief Executive Officer
Tel: +61 7 3340 0200
Tel: +61 4 0959 6164
Investor Relations USA
Blueprint Life Science Group
+1 415 375 3340 Ext. 103
Media enquiries, Australia
Emma Power or Rudi Michelson
+61 3 9620 3333
Dec. 4, 2016 12:30 AM EST Reads: 1,773
Dec. 3, 2016 11:00 PM EST Reads: 4,131
Dec. 3, 2016 11:00 PM EST Reads: 949
Dec. 3, 2016 09:30 PM EST Reads: 1,764
Dec. 3, 2016 09:30 PM EST Reads: 1,599
Dec. 3, 2016 08:00 PM EST Reads: 1,744
Dec. 3, 2016 08:00 PM EST Reads: 3,953
Dec. 3, 2016 06:15 PM EST Reads: 1,513
Dec. 3, 2016 05:30 PM EST Reads: 4,045
Dec. 3, 2016 05:15 PM EST Reads: 2,138
Dec. 3, 2016 05:15 PM EST Reads: 2,001
Dec. 3, 2016 04:30 PM EST Reads: 1,476
Dec. 3, 2016 04:00 PM EST Reads: 4,862
Dec. 3, 2016 03:30 PM EST Reads: 1,591
Dec. 3, 2016 03:15 PM EST Reads: 3,225